


CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

R. Craig Tucker

Type or print name of person signing certification



Signature

Date

November 5, 2008

PATENT APPLICATION**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****Before the Board of Patent Appeals and Interferences**

First Appellant: BLANCO-PILLADO, Maria-Jesus

Group Art Unit:

Serial No.: 10/552,131

1625

Filed: April 14, 2004

Examiner:

Chang, Celia C

PCT Nat'l Entry

Date (if applicable): October 11, 2005

For: (PIPERIDINYLOXY)PHENYL,
(PIPERIDINYLOXY)PYRIDINYL,
(PIPERIDINYLSULFANYL)PHENYL AND
(PIPERIDINYLSULFANYL)PYRIDINYL COMPOUNDS
AS 5-HT1F AGONISTS

Docket No.: X14441

BRIEF FOR APPLICANTS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to a Notification of Non-Compliant Appeal Brief, incorrect heading and missing appendix, Appellants herein submit the corrected sections. Heading 5 (v) has been amended to recite "Summary of Claimed Subject Matter", instead of original, improper "Summary of Invention". Heading X "Related proceedings appendix", missing in the original, is herein submitted, noting that the content of the appendix is "None".

Summary of Claimed Subject Matter

In general, the present invention is drawn to a family of compounds discovered to be potent and selective 5-HT_{1F} agonists, to pharmaceutical compositions containing said compounds, and to methods of treatment or prevention of migraine using said compounds.

Specifically, independent Claim 1 as amended is drawn to compounds of formula I, as found on page 3, line 16 through page 4, line 15, of the specification as filed, as limited by preferred embodiment 42), found at page 14, lines 12-15, of the Specification as filed.

Independent Claim 9 is drawn to pharmaceutical compositions comprising the compounds according to Claim 1, as described in the Specification at page 4, lines 16-18, and page 170, line 24 through page 173, line 19.

Independent Claim 14 is drawn to a method of treatment or prevention of migraine using the compounds of the invention as limited in Claim 1, as described in the Specification at page 5, lines 5-8, and page 163, line 3, through 167, line 25.

Independent Claim 29 is drawn to compounds of formula I, as found on page 3, line 16 through page 4, line 15, of the specification as filed, as limited by preferred embodiment 10) (page 12, lines 31-32) combined with preferred embodiment 40) (page 14, lines 8-9), said combination as described for further preferred embodiments at page 14 lines 24-27 of the Specification as filed.


Independent Claim 30 is drawn to pharmaceutical compositions comprising the compounds according to Claim 29, as described in the Specification at page 4, lines 16-18, and page 170, line 24 through page 173, line 19.

Independent Claim 31 is drawn to a method of treatment or prevention of migraine using the compounds of the invention as limited in Claim 29, as described in the Specification at page 5, lines 5-8, and page 163, line 3, through 167, line 25.

Related Proceedings Appendix

(None)

Respectfully submitted,



R. Craig Tucker
Attorney/Agent for Applicant(s)
Registration No. 45,165
Phone: 317-433-9829

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

November 5, 2008